Complement C5 (C5) Mouse Monoclonal Antibody [Clone ID: 2942]

Specifications

Product Data
Clone Name	2942
Applications	ELISA, FN, IHC, WB
Recommend Dilution	Immunohistochemistry on Frozen Sections: Tissue sections were fixed in Histochoice MB and treated with levamisole to quench endogenous alkaline phosphatases. As negative control the primary antibody was omitted (Ref.1). The typical starting working dilution is 1/50. Functional Assays. Immunoassays. Western blot: A reduced sample treatment and SDS-Page was used. The band size is 14 kDa. The typical starting working dilution is 1/50. Positive Control: Eye tissue  of patient with AMD (Ref.1). Negative Control: Eye tissue of patient without AMD (Ref.1).
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Specificity	Monoclonal antibody 2942 reacts with a neo-epitope on human C5a/C5a des-Arg that is formed by proteolytic cleavage of C5 into C5a and C5b during complement activation.
Formulation	PBS State: Purified State: Liquid 0.2 μm filtered Ig fraction Stabilizer: 0.1% BSA
Concentration	lot specific
Purification	Protein G Chromatography
Conjugation	Unconjugated
Storage Condition	Store undiluted at 2-8°C. DO NOT FREEZE!
Gene Name	complement component 5
Database Link	Entrez Gene 727 Human UniProt ID P01031
Background	C5a is a single chain glycopeptide composed of 74-amino-acids, which is rapidly converted to the less potent derivate C5a des-Arg upon removal of the C-terminal arginine by carboxypeptidase B. C5a acts as a potent anaphylatoxin by binding to its high affinity receptor C5aR (or CD88) on the membrane of target cells inducing smooth muscle contraction, increased vascular permeability, degranulation of mast cells and basophils, and the release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. Elevation of C5a is associated with increased cardiovascular risk in patients with advanced atherosclerosis. Also, C5a is closely associated with the capillary leak syndrome in leukemic children after bone marrow transplantation. C5a is also a marker in urine for predicting the onset of acute graft rejection after kidney transplantation and has been shown to be present in extracellular deposits in patients suffering from age-related macular degeneration (AMD).
Synonyms	Complement C5 alpha chain, C5a anaphylatoxin, CPAMD4
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.